The association between CKD-associated pruritus and quality of life in patients undergoing hemodialysis in Pakistan

Rehman, Inayat Ur; Chan, Kok‐Gan; Munib, Syed; Lee, Learn‐Han; Khan, Tahir Mehmood

doi:10.1097/md.0000000000016812

Cited by 14 publications

(22 citation statements)

References 34 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, several previous studies have acknowledged similar patient profiles. 4 , 10 , 15 , 16 Therefore, those on treatment for a longer time are assumed to have better discipline in observing the schedule, despite some impending obstacles. This disposition resulted from the benefits perceived from participating in therapy sessions.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of patients undergoing hemodialysis during Covid-19 pandemic

2021

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Characteristics of patients undergoing hemodialysis during Covid-19 pandemic

2021

View full text Add to dashboard Cite

“…STS can cause side effects, such as severe but transient nausea and vomiting [50]. Mild hypernatremia, hypokalemia, or hypocalcemia (not significant) or a mild increase in the corrected QT interval (not significant) might also be side effects [51]. Another study demonstrated that neither potassium nor sodium accumulated in the circulating blood when STS was infused in conjunction with HD [52].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effect of intravenous sodium thiosulfate for uremic pruritus in hemodialysis patients

et al. 2020

View full text Add to dashboard Cite

Objectives: This study aimed to compare the efficacy of intravenous sodium thiosulfate (IV STS) with that of loratadine in the treatment of uremic pruritus in hemodialysis (HD) patients. Methods: This retrospective study included 44 HD patients with pruritus aged over 18 years between June 2018 and January 2020 at the Aerospace Center Hospital of China. Twenty-four HD patients received 3.2 g IV STS treatment three times per week at the end of each HD session for 8 weeks. Twenty HD patients received loratadine (10 mg/day) for 8 weeks. Pruritus intensity was measured using a visual analog scale (VAS) and the detailed pruritus score (DPS) at three time points. The safety of STS was evaluated according to adverse event symptoms and biological variable changes. Results: There was no significant difference between the STS and loratadine groups in age, sex, characteristics of pruritus, or other clinical variables before treatment. After 8 weeks of treatment, the VAS score (7.07 ± 2.56 and 2.67 ± 2.01) and DPS (30.72 ± 4.81 and 8.04 ± 2.86) decreased significantly in the STS group (p < 0.05). The mean decrease in VAS score (6.89 ± 1.98 and 6.34 ± 2.35) and DPS (28.90 ± 3.24 and 26.92 ± 2.41) in the loratadine group was not statistically significant (p > 0.05). There were no morbidities or mortalities associated with the use of either drug. All biological variables remained stable after therapy. Conclusions: STS can improve uremic pruritus in HD patients. However, literature on the subject remains lacking. Close monitoring for adverse effects is advised.

show abstract

“…The DOPPS recruited 51 062 participants from 21 countries across five study phases (DOPPS 1–5) between 1996 and 2015 [ 10 ] and 23 264 participants across DOPPS 4–6 between 2009 and 2018 [ 11 ]. Patients were asked to self-report via questionnaire the presence and severity of pruritus over a 4-week period.…”

Section: Epidemiology Of Ckd-apmentioning

confidence: 99%

“…The proportion of patients with moderate to extreme itch in DOPPS 1 and 2 (45 and 42%, respectively) was similar to that in DOPPS 4–6, where the overall prevalence of moderate to extreme itch was 37%, with no significant difference across study phases [ 8 ]. One reported difference was that participants noted less severe itch in DOPPS 5 (2012–2015) compared with DOPPS 1 (1996–2001) [ 10 ], which may suggest improvements in managing CKD-aP over time. A study of the Japanese DOPPS cohort (JDOPPS) showed that overall, 44% of patients experienced moderate to extreme pruritus, but the prevalence varied widely across centres, ranging from 20% to 70% [ 17 ].…”

Section: Epidemiology Of Ckd-apmentioning

confidence: 99%

“…However, this is an area of research interest, based on evidence of sex-specific differences in itch-related mechanisms, including mast cell activation and regulation of the opioid cannabinoid and the neurokinin 1 systems [ 1 ]. A number of observational studies, including DOPPS, have shown a greater prevalence of CKD-aP in males undergoing HD [ 3 , 10 ]. However, Ramakrishnan et al [ 16 ] found a higher prevalence of pruritus in females.…”

Section: Potential Risk Factors For Ckd-ap In Dialysis Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology and burden of chronic kidney disease-associated pruritus

Kim

Pollock

2021

Clinical Kidney Journal

View full text Add to dashboard Cite

Chronic kidney disease–associated pruritus (CKD-aP) is a common, yet underrecognized condition in patients with CKD and end-stage kidney disease (ESKD). Real-world observational studies indicate that CKD-aP affects up to 80% of ESKD patients undergoing haemodialysis (HD), with ∼40% experiencing moderate to severe itch. CKD-aP can negatively impact patients’ mental and physical health-related quality of life (HRQoL) and is also associated with sleep disturbance and depression. Several studies have found that CKD-aP is a predictor of adverse medical outcomes, including an increased risk of hospitalizations and mortality. In this article we review the literature relating to the epidemiology of CKD-aP to describe its prevalence across the treatment spectrum of CKD (non-dialysis, HD, peritoneal dialysis and transplant recipients) and to summarize potential risk factors associated with its development. We also review key data from studies that have evaluated the impact of CKD-aP on HRQoL and medical outcomes.

show abstract

The association between CKD-associated pruritus and quality of life in patients undergoing hemodialysis in Pakistan

Abstract: Supplemental Digital Content is available in the text

Cited by 14 publications

References 34 publications

Characteristics of patients undergoing hemodialysis during Covid-19 pandemic

Characteristics of patients undergoing hemodialysis during Covid-19 pandemic

Therapeutic effect of intravenous sodium thiosulfate for uremic pruritus in hemodialysis patients

Epidemiology and burden of chronic kidney disease-associated pruritus

Contact Info

Product

Resources

About